The Brazilian Rare Earths Ltd (ASX: BRE) share price is in focus after announcing Alurion Resources’ IPO successfully raised $50 million, exceeding maximum subscription, with Brazilian Rare Earths retaining a 16% stake in the newly listed company.

What did Brazilian Rare Earths report?

• Alurion Resources IPO raised the maximum A$50 million, issuing 47,619,048 new shares at A$1.05 each
• Alurion’s implied equity value post-IPO is A$256 million
• Brazilian Rare Earths retains a strategic holding of 39 million Alurion shares, or roughly 16%, valued at A$41 million
• Alurion directors and management subscribed for over A$4.5 million worth of shares
• Admission to the ASX is expected on 30 July 2026, trading from 3 August 2026 under code ‘ALU’

What else do investors need to know?

Alurion’s strong IPO demand included priority access for eligible Brazilian Rare Earths shareholders, and capped the offer at its maximum subscription. This financial boost allows Alurion to pursue an expanded two-year development program at the Amargosa Bauxite-Gallium Project, funding activities like land procurement, environmental work, and exploration.

Following shareholder approval for the Demerger, Brazilian Rare Earths can now narrow its focus to advancing its core rare earth and critical minerals assets. The upcoming Monte Alto Scoping Study in August 2026 is cited as Brazilian Rare Earths’ next key milestone.

What did Brazilian Rare Earths management say?

Managing Director and CEO Bernardo da Veiga said:

Investor demand exceeding the A$50 million maximum, following 99.94% shareholder approval, highlights the strong market and shareholder support for the Alurion Resources demerger… For BRE, this successful outcome sharpens our own focus. We can now direct our full attention and capital toward advancing our important rare earth and critical mineral province, with the Monte Alto Scoping Study due in August 2026 standing as our next major catalyst.

What’s next for Brazilian Rare Earths?

With the Alurion IPO completed, Brazilian Rare Earths plans to concentrate on advancing its flagship Monte Alto project and the broader Brazilian rare earths province. The company now enjoys a stronger financial position and a strategic holding in Alurion, keeping exposure to the bauxite-gallium sector without funding dilution.

Investors can expect further operational updates from Brazilian Rare Earths as it progresses its project pipeline, with upcoming news anticipated from the Monte Alto Scoping Study.

Brazilian Rare Earths share price snapshot

Over the past 12 months, Brazilian Rare Earths shares have risen 38%, outperforming the All Ordinaries Index (ASX: XAO), which is flat over the same period.

View Original Announcement

The post Brazilian Rare Earths share price rises as Alurion IPO raises $50 million appeared first on The Motley Fool Australia.

More reading

• How many Cochlear shares do I need to buy for $10,000 of passive income?
• Why this top expert thinks Qantas shares can fly 20% higher
• Why NAB’s business banking edge makes it a buy at $39.30
• Meeka Metals June 2026 quarter: Production edges up, strong outlook with underground focus
• How much do I need in superannuation to receive $5000 per month in passive income?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Regal Partners Ltd (ASX: REG) share price is in focus today after the company reported preliminary 1H26 results, with normalised NPAT expected to double to at least $90 million and record net FUM inflows of over $1.3 billion for the half.

What did Regal Partners report?

• Normalised NPAT for 1H26 expected to be at least $90 million, up about 100% on 1H25
• Management fees for 1H26 anticipated at least $110 million
• Performance fees estimated to reach at least $115 million for 1H26
• Funds under management (FUM) grew 6% in the June quarter to approximately $21.4 billion
• Net FUM inflows hit a record $0.9 billion for the quarter, over $1.3 billion for the half

What else do investors need to know?

Regal Partners attributed strong performance fees to its PM Capital global strategy and robust flows across hedge funds, resources, and royalty strategies. The June quarter included the first close of the Taurus Mining Finance Fund III, raising around US$0.7 billion, contributing significantly to net inflows.

Partially offsetting these gains was the reduction in water entitlement assets under management, relating to the Commonwealth Government’s water buy-back program, which saw about $0.5 billion realised for institutional investors. Preliminary figures remain subject to final reviews and audit.

What’s next for Regal Partners?

The company will release its full 1H26 results on 24 August 2026 and remains focused on growing assets across its diverse investment strategies. Management flagged continued innovation in alternative investments and ongoing commitment to expanding Regal’s offering for institutional, family office, and private investors.

Investors can expect more details on outlook and strategy, as well as further updates on FUM and performance, at the official half-year results presentation.

Regal Partners share price snapshot

Over the past 12 months, Regal Partners shares have risen 7%, outperforming the All Ordinaries Index (ASX: XAO), which is flat over the same period.

View Original Announcement

The post Regal Partners: Profit doubles and FUM hits record high appeared first on The Motley Fool Australia.

More reading

• How much do I need in my superannuation to get $1000 per week in passive income?
• 3 companies to own for a dividend yield above 5%
• Could this be the best ASX dividend share to buy now?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Telix Pharmaceuticals Ltd (ASX: TLX) shares received a nice boost yesterday after the company released Q2 2026 results.

Telix Pharmaceuticals is a pharmaceutical group specialising in the development and commercialisation of radio pharmaceuticals for the imaging and treatment of certain cancers.

What did the company report yesterday?

As The Motley Fool’s Bernd Struben reported, the company announced: 

• 21% year-on-year revenue boost to US$247 million (AU$353 million). 
• Second-quarter revenue rise of 7% from the prior quarter.
• The company’s Precision Medicine segment brought in US$202 million of that quarterly revenue, a 30% increase from Q2 2025 and up 9% from last quarter.

The company said it expects FY 2026 revenue and other income to be in excess of US$1 billion, with revenue tracking in line with the upper end of FY 2026 guidance of US$950 million to US$970 million.

Speaking on the results, Dr Christian Behrenbruch, Managing Director and Group CEO, said: 

We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA7 imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix’s market leadership, built on clinical differentiation, supply chain resilience and commercial execution.

Following these results, Bell Potter released updated guidance on Telix shares. 

Solid growth 

Bell Potter’s report yesterday shows the broker sees the results largely as positive. 

Telix is growing faster than expected and appears to be gaining market share in PSMA imaging; it is confident enough to invest more in research and still expects strong underlying sales even without the one-off Regeneron payment.

Other than the half year result in August, the major upcoming catalyst is the FDA decision on approval of Pixclara for brain cancer imaging, due 11 September 2026. 

This pending approval represents a pivotal moment. Approval would likely generate a welcome re-rating. A second Complete Response Letter (CRL), depending on the nature of the contents, could be highly damaging as there are no other near to revenue pipeline products. 

In the clinic, we expect the FDA should clear the amended IND for TLX591 in the coming weeks, finally allowing recruitment of the Part 2 of this trial to commence recruitment in the US.

Healthy upside for Telix shares 

Based on this guidance, the team at Bell Potter has retained its buy recommendation for Telix shares. 

The broker has maintained its 12-month price target of $19. 

Based on yesterday’s closing price, this indicates upside potential of almost 26%. 

The post Are Telix shares a buy, hold or sell following results? appeared first on The Motley Fool Australia.

More reading

• Up 79% since February, why are Telix shares jumping higher again on Tuesday?
• Top 3 ASX healthcare stocks to watch
• Telix Pharmaceuticals: Q2 2026 revenue jumps 21%
• These are the 10 most shorted ASX shares
• Down 9%: Is the rebound over for Telix shares?

Motley Fool contributor Aaron Bell has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.